pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·3 min read
save

STAT+: Comments on OMB research rule mysteriously removed from federal website

Some comments on a proposed OMB research rule have been mysteriously removed from a public-facing government webpage.

Aug 25, 2026·read at STAT ↗

STAT PlusPolitics Comments on OMB research rule mysteriously removed from federal website Agency pulls posts mentioning CF diagnosis of director Russell Vought’s daughter Manage alerts for this article Email this article Share this article By Anil OzaAug. 25, 2026 General Assignment Reporter Anil Oza[email protected]Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16.

For the past couple of years, Magdeleine Bradford-Butcher has been living on the cutting edge of science. When prenatal testing showed the baby she was carrying had cystic fibrosis, her doctor put her on Trikafta — a relatively new treatment aimed at preventing severe complications from the genetic disease after birth. Trikafta and other advances have dramatically changed the outlook for children with CF, but she was taken aback when, as she recalls, one of the physicians told her after the delivery, “With all of the new developments, your daughter has a very good chance of outliving you.” It was a glimmer of optimism amid a scary diagnosis.

“Nobody had said that to me before, and that was incredible,” she said. “That’s something I treasure.”Advertisement So when she heard about a pending White House regulation that would open federal science funding to more political intervention, she was concerned. With the encouragement of the Cystic Fibrosis Foundation and a favorite science influencer, Jessica Knurick, she decided to submit a public comment on the proposal describing how she had benefited from research funding.

“Seeing how quickly they could revoke grants when that was so crucial to so much research was very disturbing. So that’s the basis of why I commented,” she said in an interview. She worried that the proposed wholesale rewrite of laws undergirding all federal contracts, including research grants, could affect work on other children’s diseases, but also a study her daughter was involved in, examining the outcomes of children who had been given Trikafta in utero.

“I was really worried about whether or not that project could get cut for any arbitrary reason.” What happened next was unusual, according to legal experts, and mysterious. Soon after Bradford-Butcher’s comment was publicly posted on the federal government’s regulations.gov website, it was taken down without explanation by the White House Office of Management and Budget. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In research, STAT+, White House Submit a correction requestReprints Anil Oza General Assignment Reporter Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity.

You can reach him on Signal at aniloza.16. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Unraveled August 25, 2026 How Trump’s cuts are reshaping America’s health system Health Care Inc. Newsletter August 24, 2026 STAT Plus: Public-sector purgatory, and a union-hospital fight Advertisement Politics August 24, 2026 STAT Plus: Medicaid transgender care rule sets precedent that could restrict coverage of other drugs Health August 24, 2026 Americans bought 12% less soda under new SNAP restrictions, study says Health August 21, 2026 STAT Plus: HHS document offers new clues to Kennedy’s vaccine plans Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
636 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

drugs
(elexacaftor + ivacaftor + tezacaftor) + ivacaftor3
topics
Cystic Fibrosis2Vaccine

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 5d agoKolon TissueGene cuts 37 US staffers after Phase 3 failBioSpace
  • Aug 10Sionna cystic fibrosis drug fails key trial, removing threat to VertexBioPharma Dive
  • Aug 10Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchiseBioSpace
  • Aug 10STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trialSTAT